AMd (AMD) said via X that it is partnering with drug-discovery company Absci (ABSI). “AMD is proud to announce we are partnering with @abscibio to accelerate the future of AI drug discovery. Absci will deploy AMD high-performance compute and software to advance development of next-gen antibody therapeutics and transform creation of biologics for patients.”
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABSI:
- Absci, AMD announce collaboration, strategic investment
- Absci price target lowered to $5 from $6 at KeyBanc
- Absci, Invetx partner to bring AI drug creation platform to animal health
- Absci highlights progress, updates across proprietary pipeline
- Cathie Wood’s ARK Investment bought 202.6K shares of Absci today
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
